1. At a Glance – The Multinational With Desi Mood Swings
Pfizer Ltd is currently trading at ₹5,198, commanding a market cap of ₹23,760 crore. Stock P/E stands at 31.2, slightly above industry median (29.8), ROCE at 21.6%, ROE at 16.4%, and dividend yield at 0.67%.
Last 3 months return? A modest 3.06%.
Last 1 year return? A spicy 26.4%.
Now the juicy bit — Q3 FY26 (Dec 2025 quarter):
- Revenue: ₹645 crore
- PAT: ₹141.84 crore
- OPM: 35%
- QoQ sales growth: 19.9%
- QoQ profit growth: 43%
- Exceptional charge: ₹58.20 crore
- Other income: –₹20 crore
This quarter also includes a headline-grabbing exclusive marketing deal with Cipla and a bunch of management reshuffles.
So the question is:
Is this a steady global pharma giant flexing its muscle?
Or a legacy MNC trying to reinvent itself in India while juggling GST notices and marketing agreements?
Let’s open the case file.
2. Introduction – The MNC With A Complicated Indian Story
Pfizer Ltd is not some random smallcap pharma hopeful. It is the Indian arm of global behemoth Pfizer Inc., which operates in over 125 countries and develops medicines across immunology, oncology, cardiology, endocrinology and neurology.
In India, Pfizer Ltd calls itself the 3rd largest multinational pharmaceutical company. That’s not a small claim.
The company manufactures through:
- Its own facility in Goa
- 18 Contract Manufacturing Organizations (CMOs)
- 15 warehousing partners
- A distribution network reaching 2,00,000+ healthcare providers
- 2,50,000+ pharmacies
- 1,800 hospitals
Basically, if you’ve swallowed a branded cough syrup or vaccine in India, there’s a fair chance Pfizer had something to do with it.
But here’s where the plot thickens:
Between FY22 and FY24, revenue declined 16% — thanks to:
- Voluntary recall of Magnex, Zosyn, Magnamycin (May 2023)
- NLEM 2022 price ceiling revisions
So while global Pfizer was busy printing vaccine money globally, Indian Pfizer was dealing with recalls and price controls.
Classic desi twist.
3. Business Model – WTF Do They Even Do?
Let’s simplify.
Pfizer India does four main things:
1️ Vaccines
Their superstar here is Prevenar 13, a pneumococcal conjugate vaccine.
In the private pneumococcal vaccines market:
- Unit share: 52%
- Value share: 64.8%
Translation:
They dominate this niche like Shah Rukh dominates NRI weddings.
2️ Internal Medicine
Includes brands like:
- Corex Dx
- Corex LS
- Ativan
- Pacitane
- Minipress XL
- Gelusil
- Mucaine
- Neksium
Corex Dx holds 15% market share in dry cough segment.
3️ Hospital Business
Advanced anti-infectives like:
4️ Inflammation & Immunology
Products like:
Now here’s the twist — December 2025:
Pfizer signed an exclusive five-year marketing agreement with Cipla for:
- Corex Dx
- Corex LS
- Dolonex
- Neksium
So instead of marketing some brands themselves, they handed them to Cipla.
Strategic partnership?
Or slimming down operations?
What do you think?
4. Financials Overview – Numbers Don’t Lie (But They Sometimes Confuse)
EPS Annualisation Rule (Q3)
Average of Q1, Q2, Q3 EPS × 4
- Q1 FY26 EPS (Jun 2025): ₹41.91
- Q2 FY26 EPS (Sep 2025): ₹41.32
- Q3 FY26 EPS (Dec 2025): ₹31.00
Average EPS = (41.91 + 41.32 + 31.00) / 3 = ₹38.08
Annualised EPS = 38.08 × 4 = ₹152.32
Now, recalculated P/E:
Current price ₹5,198
P/E = 5198 / 152.32 ≈ 34.1
Reported P/E is 31.2 (based on TTM EPS ₹186.57).
Our annualised Q3-based
